Dr. Than Aye, MD
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,528 | 288 | 44.1% |
| Consulting Fee | $4,043 | 3 | 39.4% |
| Travel and Lodging | $1,319 | 4 | 12.9% |
| Honoraria | $200.00 | 1 | 1.9% |
| Education | $167.77 | 20 | 1.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $4,273 | 11 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $1,650 | 27 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $568.88 | 44 | $0 (2020) |
| Genentech USA, Inc. | $522.19 | 33 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $241.29 | 18 | $0 (2020) |
| Janssen Biotech, Inc. | $216.52 | 14 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $212.11 | 19 | $0 (2019) |
| Novocure GmbH | $200.00 | 1 | $0 (2022) |
| Exelixis Inc. | $194.11 | 15 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $184.17 | 14 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,251 | 3 | AstraZeneca Pharmaceuticals LP ($1,225) |
| 2023 | $4,236 | 8 | Incyte Corporation ($4,217) |
| 2022 | $269.76 | 2 | Novocure GmbH ($200.00) |
| 2021 | $136.92 | 2 | GlaxoSmithKline, LLC. ($125.00) |
| 2020 | $82.30 | 6 | Amgen Inc. ($19.86) |
| 2019 | $1,119 | 66 | Genentech USA, Inc. ($226.11) |
| 2018 | $1,727 | 120 | Novartis Pharmaceuticals Corporation ($275.61) |
| 2017 | $1,435 | 109 | Novartis Pharmaceuticals Corporation ($227.23) |
All Payment Transactions
316 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Genentech USA, Inc. | Columvi (Biological), Gazyva, Lunsumio | Food and Beverage | In-kind items and services | $26.35 | General |
| Category: BioOncology | ||||||
| 11/25/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $825.00 | General |
| 02/19/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| Category: Oncology | ||||||
| 12/27/2023 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $19.03 | General |
| Category: Oncology | ||||||
| 03/31/2023 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $34.55 | General |
| 03/16/2023 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $2,818.00 | General |
| 03/16/2023 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $229.00 | General |
| 03/16/2023 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $229.00 | General |
| 03/16/2023 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $222.68 | General |
| 03/16/2023 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $46.15 | General |
| 02/24/2023 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $637.92 | General |
| 11/01/2022 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $69.76 | General |
| Category: Oncology | ||||||
| 01/19/2022 | Novocure GmbH | — | Honoraria | Cash or cash equivalent | $200.00 | General |
| 12/08/2021 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 09/03/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | Cash or cash equivalent | $11.66 | General |
| Category: Oncology | ||||||
| 02/11/2020 | Amgen Inc. | Prolia (Biological), XGEVA | Food and Beverage | In-kind items and services | $19.86 | General |
| Category: Bone Health | ||||||
| 02/06/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological), LENVIMA | Food and Beverage | In-kind items and services | $11.78 | General |
| Category: ONCOLOGY | ||||||
| 01/21/2020 | Seagen Inc. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $13.52 | General |
| Category: Oncology | ||||||
| 01/14/2020 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Food and Beverage | In-kind items and services | $13.00 | General |
| Category: ONCOLOGY | ||||||
| 01/11/2020 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $12.48 | General |
| Category: Hematology | ||||||
| 11/21/2019 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $19.52 | General |
| Category: Oncology | ||||||
| 11/19/2019 | PFIZER INC. | IBRANCE (Drug), TALZENNA | Food and Beverage | In-kind items and services | $13.62 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2019 | Genentech USA, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $11.94 | General |
| Category: BioOncology | ||||||
| 11/14/2019 | Genentech USA, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $5.16 | General |
| Category: BioOncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 643 | 1,173 | $538,987 | $99,544 |
| 2022 | 7 | 647 | 1,048 | $419,848 | $92,803 |
| 2021 | 7 | 609 | 971 | $307,623 | $81,664 |
| 2020 | 6 | 587 | 888 | $224,461 | $57,167 |
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 213 | 446 | $238,610 | $44,208 | 18.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 286 | 565 | $215,265 | $37,335 | 17.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 80 | 80 | $52,080 | $10,422 | 20.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 28 | 34 | $19,394 | $4,273 | 22.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 26 | $7,720 | $2,321 | 30.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 22 | 22 | $5,918 | $984.02 | 16.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 184 | 374 | $173,536 | $40,172 | 23.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 268 | 464 | $154,512 | $31,463 | 20.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 78 | 78 | $44,070 | $11,076 | 25.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 24 | 27 | $14,013 | $3,968 | 28.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 51 | 63 | $20,979 | $3,668 | 17.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 15 | 15 | $6,420 | $1,418 | 22.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 27 | 27 | $6,318 | $1,038 | 16.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 263 | 516 | $144,996 | $36,803 | 25.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 121 | 216 | $81,648 | $23,813 | 29.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 75 | 75 | $39,975 | $10,607 | 26.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 74 | 84 | $16,296 | $3,651 | 22.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 45 | 48 | $9,555 | $2,850 | 29.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 16 | 17 | $8,823 | $2,661 | 30.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 15 | 15 | $6,330 | $1,281 | 20.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 185 | 311 | $83,663 | $17,163 | 20.5% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 175 | 256 | $32,404 | $16,008 | 49.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 113 | 195 | $70,148 | $15,676 | 22.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 38 | 38 | $19,706 | $4,930 | 25.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 64 | 76 | $13,830 | $2,415 | 17.5% |
About Dr. Than Aye, MD
Dr. Than Aye, MD is a Student in an Organized Health Care Education/Training Program healthcare provider based in Lawton, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/22/2009. The National Provider Identifier (NPI) number assigned to this provider is 1104053792.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Than Aye, MD has received a total of $10,257 in payments from pharmaceutical and medical device companies, with $1,251 received in 2024. These payments were reported across 316 transactions from 45 companies. The most common payment nature is "Food and Beverage" ($4,528).
As a Medicare-enrolled provider, Aye has provided services to 2,486 Medicare beneficiaries, totaling 4,080 services with total Medicare billing of $331,178. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Hematology & Oncology
- Location Lawton, OK
- Active Since 06/22/2009
- Last Updated 07/14/2015
- Taxonomy Code 390200000X
- Entity Type Individual
- NPI Number 1104053792
Products in Payments
- IMFINZI (Biological) $400.00
- GILOTRIF (Drug) $212.11
- IMFINZI (Drug) $204.53
- Cabometyx (Drug) $194.11
- KEYTRUDA (Biological) $193.83
- OPDIVO (Biological) $154.20
- ZEJULA (Drug) $153.29
- MEKINIST (Drug) $139.79
- Kadcyla (Biological) $131.13
- DARZALEX (Biological) $130.24
- Imbruvica (Drug) $128.10
- AFINITOR (Drug) $122.13
- BENDEKA (Drug) $114.29
- JEVTANA (Drug) $111.56
- Xtandi (Drug) $103.61
- Perjeta (Biological) $102.24
- Aranesp (Biological) $92.60
- NINLARO (Drug) $92.01
- TECENTRIQ (Biological) $88.90
- PROMACTA (Drug) $88.36
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in Lawton
Dr. Lauren Lunday, Dds, DDS
Student in an Organized Health Care Education/Training Program — Payments: $983.44
Nathan Blacker, Do, DO
Student in an Organized Health Care Education/Training Program — Payments: $263.95
Eric Sparks
Student in an Organized Health Care Education/Training Program — Payments: $143.58
Shelby Willis, Do, DO
Student in an Organized Health Care Education/Training Program — Payments: $143.45
Christopher Benson, Do, DO
Student in an Organized Health Care Education/Training Program — Payments: $112.72
Rick Campos, Dmd, DMD
Student in an Organized Health Care Education/Training Program — Payments: $82.82